Apr 29 |
Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
|
Apr 29 |
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
|
Apr 28 |
11 Oversold Growth Stocks to Buy Right Now
|
Apr 25 |
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
|
Apr 25 |
Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma
|
Apr 25 |
Regeneron (REGN) Reports Next Week: What You Should Expect
|
Apr 25 |
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
|
Apr 25 |
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
|
Apr 25 |
Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies
|
Apr 25 |
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
|